Thrombocythaemia Myelofibrosis:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)

◆英語タイトル: Thrombocythaemia Myelofibrosis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
◆商品コード:DIIR2014480
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2014年版(※最新版はお問い合わせください)
◆ページ数:75以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s, “ Thrombocythaemia Myelofibrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


• A snapshot of the global Market therapeutics scenario for Thrombocythaemia Myelofibrosis.
• A review of the marketed products under prescription for Thrombocythaemia Myelofibrosis, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Thrombocythaemia Myelofibrosis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Thrombocythaemia Myelofibrosis drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Thrombocythaemia Myelofibrosis drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Thrombocythaemia Myelofibrosis drugs.
• Coverage of Thrombocythaemia Myelofibrosis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2011-2015.

• Evaluate the marketing status and exclusivity details of Thrombocythaemia Myelofibrosis key products to exploit opportunities for generic drug development opportunities.
• Identify and understand important and diverse types of therapeutics under Phase III development for Thrombocythaemia Myelofibrosis.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Thrombocythaemia Myelofibrosis.
• API intelligence over marketed drugs for Thrombocythaemia Myelofibrosis and gaining primary intelligence over active ingredients manufacturers across the globe.
• API intelligence over leading Phase III pipeline drugs.
• Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
• Understanding the scope of the Phase III Drugs with nil regulatory filings.
• Understanding the chemical route of synthesis of approved drugs for Thrombocythaemia Myelofibrosis.
• Uncovering opportunities in the rapidly growing the US markets.

【レポートの目次】

• Indication Overview
• Marketed Drugs Assessment
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• The API Manufacturers by the United States Drug Master File (US DMF) Status
• The API Manufacturers by the US DMF Status (Drug Specific)
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
• The API Manufacturers by the US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figures (2011-2015)
• Marketed Drugs Information
• Drugs Description
• Route of Synthesis
• Global Active Pharmaceutical Manufacturers
• Approval Status
• Patent and Exclusivity Details
• Company Overview
• Phase III Drugs Information
• Phase III Drugs Description
• The United States Drug Master Filings (US DMF)
• Discontinued Drugs Information

Thrombocythaemia Myelofibrosis Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, US, (Year), 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, API Manufacturers by US DMF Status, 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Thrombocythaemia Myelofibrosis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, Global Sales (in million USD), 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, API Manufacturers, Global, 2014
Thrombocythaemia Myelofibrosis Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Thrombocythaemia Myelofibrosis, 2014

Thrombocythaemia Myelofibrosis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, US, (Year), 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Thrombocythaemia Myelofibrosis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Thrombocythaemia Myelofibrosis Therapeutic Market, Global Sales (in million USD), 2014
Thrombocythaemia Myelofibrosis Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

【掲載企業】

Incyte Corporation

【レポートのキーワード】

Thrombocythaemia Myelofibrosis、医薬品、治療薬、規模、販売量、医薬品有効成分(API)メーカー、第Ⅲ相試験、製薬

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Thrombocythaemia Myelofibrosis:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆